Irene Ghobrial

Director, Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute

Appears in 1 story

Stories

Teclistamab shows deep remissions in high-risk smoldering myeloma trial

New Capabilities

Co-investigator on the ImmunoPRISM trial

Doctors at Dana-Farber Cancer Institute gave teclistamab, a bispecific antibody already approved for advanced myeloma, to 45 patients with high-risk smoldering multiple myeloma. Complete remission followed in 77.8% of them.

Updated 2 hours ago